OS Therapies Extends Warrant Inducement Offering Period

The latest announcement is out from OS Therapies Incorporated ( (OSTX) ).

On January 10, 2026, OS Therapies Incorporated entered into inducement offer letter agreements with fewer than 10 accredited investors who hold existing warrants to purchase up to 5,382,148 shares of common stock. Under these agreements, the investors agreed to exercise or pre-fund their existing warrants for cash at a reduced exercise price of $1.40 per share (or $1.399 per share for pre-funded exercises) in exchange for new warrants to purchase the same number of shares at $1.40 per share, subject to adjustment.

On February 10, 2026, the company, with the consent of its warrant solicitation agent, extended the offering period for this inducement transaction from its original expiration at 11:59 p.m. Eastern time on February 10, 2026, to 11:59 p.m. Eastern time on March 2, 2026. The extension gives OS Therapies additional time to secure warrant exercises and associated cash proceeds, potentially strengthening its balance sheet and funding capacity while deepening engagement with a small group of accredited investors.

The most recent analyst rating on (OSTX) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.

Spark’s Take on OSTX Stock

According to Spark, TipRanks’ AI Analyst, OSTX is a Neutral.

The score is held down primarily by weak financial performance (no revenue, widening losses, and continued cash burn) and negative-to-neutral technical momentum (below key moving averages with negative MACD). A recent capital raise that reportedly extends runway into 2027 helps mitigate near-term liquidity risk, but valuation remains constrained by ongoing losses and the lack of a dividend.

To see Spark’s full report on OSTX stock, click here.

More about OS Therapies Incorporated

OS Therapies Incorporated operates in the biopharmaceutical sector, focusing on developing therapies that are financed in part through equity-linked securities such as common stock and associated warrants. The company engages accredited investors through structured warrant agreements, reflecting a capital-raising strategy that relies on institutional and high-net-worth participants in the healthcare investment market.

Average Trading Volume: 548,324

Technical Sentiment Signal: Sell

Current Market Cap: $42.26M

See more insights into OSTX stock on TipRanks’ Stock Analysis page.